Philips Respironics Has Voluntarily Recalled Certain Ventilators, BiPAP, and CPAP Machines.
On June 20, 2021, the U.S. Food and Drug Administration (FDA) announced that it was alerting people who use Philips Respironics ventilators, BiPAP, and CPAP machines and their health care providers that Philips Respironics has recalled certain devices manufactured between 2009 and April 26, 2021 due to potential health risks.
According to the FDA safety communication, the polyester-based polyurethane (PE-PUR) sound abatement foam, which is used to reduce sound and vibration in affected Philips Respironics devices, may break down and potentially enter the device’s air pathway. If this happens, black debris from the foam or certain chemicals released into the device’s air pathway may be inhaled or swallowed by the person using the device.
The Philips CPAP and BiPAP devices that were recalled include:
Device Type | Model |
Continuous Ventilator, Minimum Ventilatory Support, Facility Use | E30 (Emergency Use Authorization) |
Continuous Ventilator, Non-life Supporting | DreamStation ASV DreamStation ST, AVAPS SystemOne ASV4 C-Series ASV C-Series S/T and AVAPS OmniLab Advanced+ |
Noncontinuous Ventilator | SystemOne (Q-Series) DreamStation DreamStation Go Dorma 400 Dorma 500 REMstar SE Auto |
The Philips ventilator devices that were recalled include:
Device Type | Model |
Continuous Ventilator | Trilogy 100 Trilogy 200 Garbin Plus, Aeris, LifeVent |
Continuous Ventilator, Minimum Ventilatory Support, Facility Use | A-Series BiPAP Hybrid A30 (not marketed in US) A-Series BiPAP V30 Auto |
Continuous Ventilator, Non-life Supporting | A-Series BiPAP A40 A-Series BiPAP A30 |
If you or a loved one have used a Philips ventilator, CPAP or BiPAP device that was the subject of the Philips ventilator, CPAP and BiPAP recall and suffered from a serious injury, you may be able to recover compensation from a Philips ventilator, BiPAP or CPAP recall lawsuit.
If You Have Thoughts On The Philips Ventilator, BiPAP and CPAP Recall, Share Your Recall Comments Below.